Answers are grounded in this paper and cite their sources.
Introduction: bisphosphonates are products commonly used for the treatment of osteoporosis, mainly for this reason; A wide variety of molecules can be found on the world market. One of the adverse side effects of these drugs is maxillary osteonecrosis reported in patients who have used these products, especially after receiving invasive dental treatments. This is a severe reaction to these drugs and several risk factors have been seen to be involved in its incidence. Objective: the objective of this work is to find scientific evidence to determine the relationship between the incidence of maxillary osteonecrosis and the use of oral bisphosphonates. Methods: a systematic search of publications on controlled clinical trials and observational studies reporting incidences of maxillary osteonecrosis in patients using bone antiresorptive agents was carried out in the DialNet, DynaMed, PubMed, MedLine, Nature, JStor, NIH and SciencDirect databases. Results: t was found that the incidence of maxillary osteonecrosis considerably variable depending on the clinical condition of the patient receiving treatment whit bisphosphonates. Conclusion: osteonecrosis due to consumption of bisphosphonates is a low frequency pathology, its incidence is directly modified by factors such as polypharmacy and type of underlying pathology, as well as the type of bisphosphonate molecules, dose, and time of exposure to them
No takes yet. Share an insight, caveat, or question.
Brun et al. (2023) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: